(59 days)
No
The description details a standard automated wet chemistry analyzer and reagent cartridge, with no mention of AI or ML in the device operation, data analysis, or performance studies.
No.
Explanation: The device is an in-vitro diagnostic instrument and reagent cartridge for measuring alkaline phosphatase activity, which assists in diagnosing diseases but does not provide direct therapy.
Yes
The device, described as "The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for the quantitative measurement of alkaline phosphatase activity in serum, lithium heparinized plasma, or sodium citrate plasma," is explicitly stated to be used for "diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases." This directly aligns with the definition of a diagnostic device.
No
The device described is a reagent cartridge for a wet chemistry analyzer, which is a physical component used in a laboratory instrument. The 510(k) summary focuses on the performance of the reagent and the analyzer system, not on standalone software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section clearly states: "For in vitro diagnostic use only."
- Intended Use: The device is intended for the "quantitative measurement of alkaline phosphatase activity in serum, lithium heparinized plasma, or sodium citrate plasma." This involves testing biological samples in vitro (outside the body).
- Clinical Context: The measurements are used "in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases," which is a clear clinical application.
- Care Setting: The intended users are "clinical laboratories or physician office laboratories," which are settings where IVD testing is performed.
N/A
Intended Use / Indications for Use
The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for the quantitative measurement of alkaline phosphatase activity in serum, lithium heparinized plasma, or sodium citrate plasma using the HITACHI Clinical Analyzer. The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
Measurements of alkaline phosphatase are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases.
Product codes
CJE
Device Description
The Hitachi Clinical Analyzer is an automatic, bench-top, wet chemistry system intended for use in clinical laboratories or physician office laboratories. The instrument consists of a desktop analyzer unit, an operations screen that prompts the user for operation input and displays data, a printer, and a unit cover. The analyzer unit includes a single probe, an incubation rotor, carousels for sample cups and reagent cartridges, and a multi-wavelength photometer. The single-use reagent cartridges may be placed in any configuration on the carousel, allowing the user to develop any test panel where the reagent cartridges are available.
The S TEST reagent cartridges are made of plastic and include two small reservoirs capable of holding two separate reagents (R1 and R2), separated by a reaction cell/photometric cuvette. The cartridges also include a dot code label that contains all chemistry parameters, calibration factors, and other production-related information, e.g., expiration dating. The dimensions of the reagent cartridges are: 13.5 mm (W) × 28 mm (D) × 20.2 mm (H).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
clinical laboratories or physician office laboratories.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A series of studies were performed that evaluated the following nonclinical performance characteristics for each analytical sensitivity (limits of detection), linearity, 20-day in-house precision, interference testing, in-house method comparisons, and matrices comparison between serum and heparin plasma.
Analytical Sensitivity (Limits of Detection): The study followed CLSI EP17-A, and the limit of detection was found to be 1.8 U/L.
Linearity: The study followed CLSI EP-6A, and the range of linearity was 5 U/L to 1,000 U/L.
20-day In-house Precision: The studies followed CLSI EP5-A2, where three levels of samples were each tested in two runs, twice a day, for 20 days.
Interference Testing: (per CLSI EP7-A2) Two serum pools containing approximately 12 mg/L and 80 U/L ALP.
Method Comparison: A total of 97 clinical specimens spanning the dynamic range (11 to 926 U/L), were assayed in singleton and in a blinded fashion by both the Hitachi system and a standard laboratory system.
Matrices Comparisons: A study was performed to validate the use of two plasma types as an alternative to serum for the Hitachi Clinical Analyzer with S TEST Reagent Cartridge Alkaline Phosphatase (ALP). The plasma types were sodium citrate and lithium heparin. Thirty-eight (38) matched serum/plasma samples that spanned the dynamic range (13 to 967) were assayed in singleton.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical Data:
- Analytical Sensitivity (Limits of Detection): Study followed CLSI EP17-A. Result: 1.8 U/L.
- Linearity: Study followed CLSI EP-6A. Range of linearity: 5 U/L to 1,000 U/L.
- 20-day In-house Precision: Studies followed CLSI EP5-A2. Three levels of samples tested, two runs, twice a day, for 20 days.
- Low (Mean 42.7 U/L): Within-Run %CV 3.1%, Total %CV 5.3%.
- Middle (Mean 80.5 U/L): Within-Run %CV 3.8%, Total %CV 5.8%.
- High (Mean 555.6 U/L): Within-Run %CV 2.5%, Total %CV 4.4%.
- Interference Testing (per CLSI EP7-A2):
- Hemoglobin: no interference up to 500 mg/dL.
- Unconjugated bilirubin: no interference up to 50 mg/dL.
- Lipemia: no interference up to 2,000 mg/dL.
- Ascorbic acid: no interference up to 50 mg/dL.
- Lack of interference defined as recoveries between 90% and 110% of the neat value.
- Method Comparison: A total of 97 clinical specimens (11 to 926 U/L) assayed:
- r = 0.996
- Slope = 0.926 (95% CI: 0.909 to 0.943)
- y-intercept = 4.8 (95% CI: -0.2 to 9.8)
- X mean = 203 U/L, Y mean = 193 U/L
- Matrices Comparisons (N = 38, Range (serum) = 13 to 967 U/L):
- Sodium Citrate Plasma: Slope = 1.03 (95% CI: 1.01 to 1.05), y-intercept = -11.2 (95% CI: -15.5 to -7.0), r = 0.999.
- Heparinized Plasma: Slope = 1.01 (95% CI: 1.00 to 1.02), y-intercept = -5.4 (95% CI: -8.3 to -2.6), r = 0.999.
Clinical Data (External POL-type sites):
- External site precision study (N = 30 replicates per sample per site): Three blinded serum samples (low, middle, high concentrations of ALP) assayed six times per day for five days.
- Site 1: Low Mean 13.2 U/L (SD 0.96, %CV 7.3%), Middle Mean 76.2 U/L (SD 2.26, %CV 3.0%), High Mean 408.6 U/L (SD 26.01, %CV 6.4%).
- Site 2: Low Mean 12.8 U/L (SD 1.00, %CV 7.8%), Middle Mean 68.8 U/L (SD 5.24, %CV 7.6%), High Mean 390.1 U/L (SD 23.21, %CV 6.0%).
- Site 3: Low Mean 13.4 U/L (SD 1.23, %CV 9.2%), Middle Mean 70.0 U/L (SD 6.28, %CV 9.0%), High Mean 402.9 U/L (SD 12.33, %CV 3.1%).
- External site method comparison study: Approximately 70 serum specimens (11 to 745 U/L) assayed on Hitachi Clinical Analyzer (y) and a comparative method (x). Least squares linear regression analysis.
- Site 1 (n=77, Range 13 to 745): Regression Equation y = 0.967x + 2.9, "r" = 0.99, 95% CI Slope 0.949 to 0.984, 95% CI Intercept -0.6 to 6.4.
- Site 2 (n=72, Range 11 to 688): Regression Equation y = 0.942x - 0.7, "r" = 0.99, 95% CI Slope 0.925 to 0.960, 95% CI Intercept -4.4 to 2.9.
- Site 3 (n=72, Range 12 to 736): Regression Equation y = 0.980x + 0.8, "r" = 0.99, 95% CI Slope 0.961 to 0.999, 95% CI Intercept -3.2 to 4.7.
Overall Conclusion: The test system was shown to be safe and effective for its intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found (Precision and Regression Statistics (r, slope, intercept) are provided)
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1050 Alkaline phosphatase or isoenzymes test system.
(a)
Identification. An alkaline phosphatase or isoenzymes test system is a device intended to measure alkaline phosphatase or its isoenzymes (a group of enzymes with similar biological activity) in serum or plasma. Measurements of alkaline phosphatase or its isoenzymes are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases.(b)
Classification. Class II.
0
HITACHI
Inspire the Next
MAR 2 2 2013
SECTION 8 510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is K130141.
| 807.92 (a)(1): Name: | Hitachi Chemical Diagnostics |
|---|---|
| Address: | 630 Clyde Court |
| Mountain View, CA 94043 | |
| Phone: | (650) 961 5501 |
| FAX: | (650) 969 2745 |
| Contact: | Mr. Charles Tsou |
807.92 (a)(2): Device name- trade name and common name, and classification
Trade name: S TEST Reagent Cartridge Alkaline Phosphatase (ALP)
Common Name: Routine chemistry analyzer for ALP
Classifications: 21 CFR § 862.1050 Alkaline Phosphatase (ALP)
807.92 (a)(3): Identification of the legally marketed predicate devices
Cobas c systems ALP2 (Roche Diagnostics, Inc., Indianapolis, IN)- K100853
807.92 (a)(4): Device Description
The Hitachi Clinical Analyzer is an automatic, bench-top, wet chemistry system intended for use in clinical laboratories or physician office laboratories. The instrument consists of a desktop analyzer unit, an operations screen that prompts the user for operation input and displays data, a printer, and a unit cover. The analyzer unit includes a single probe, an incubation rotor, carousels for sample cups and reagent cartridges, and a multi-wavelength photometer. The single-use reagent cartridges may be placed in any configuration on the carousel, allowing the user to develop any test panel where the reagent cartridges are available.
The S TEST reagent cartridges are made of plastic and include two small reservoirs capable of holding two separate reagents (R1 and R2), separated by a reaction cell/photometric cuvette. The cartridges also include a dot code label that contains all chemistry parameters, calibration factors, and other production-related information, e.g., expiration dating. The dimensions of the reagent cartridges are: 13.5 mm (W) × 28 mm (D) × 20.2 mm (H).
Page 1 of 6
| Hitachi Chemical Diagnostics, Inc. | |
|---|---|
| 630 Clyde Court, Mountain View, CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745 | |
| www.hcdiagnostics.com |
1
Image /page/1/Picture/0 description: The image shows the logo for Hitachi. The word "HITACHI" is in large, bold, black letters. Below the company name is the slogan "Inspire the Next" in a smaller font size. The logo is simple and modern.
System operation: After the sample cup is placed into the carousel, the analyzer pipettes the sample, pipettes the reagent, and mixes (stirs) the sample and reagent together. After the sample and reagent react in the incubator bath, the analyzer measures the absorbance of the sample, and based on the absorbance of the reactions, it calculates the concentration of analyte in the sample. The test system can measure analytes in serum or plasma and results are available in approximately 15 minutes per test. This submission is for Reagent Cartridge ALP.
Chemistry reactions: Alkaline phosphatase (ALP) in the sample reacts with its substrate, pnitrophenyl phosphate (p-NPP), in ethylaminoethanol (EAE) buffer, to release p-nitrophenol (yellow). The ALP activity is determined by measuring the rate of p-nitrophenol production.
807.92 (a)(5): Intended Use
The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for the quantitative measurement of alkaline phosphatase activity in serum, lithium heparinized plasma, or sodium citrate plasma using the HITACHI Clinical Analyzer. The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only,
Measurements of alkaline phosphatase are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases.
Page 2 of 6
Hitachi Chemical Diagnostics, Inc.
w.hcdjagnostics.com
530 Clyde Court, Mountain View, CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745
2
807.92 (a)(6): Technological Similarities and Differences to the Predicate
The following chart describes similarities and differences between the two test systems.
| Characteristic | Hitachi S TEST Systems | PREDICATE |
|---|---|---|
| Instrument Platform | Hitachi Clinical Analyzer | |
| (originally cleared under K111753) | Roche cobas c systems - K100853 | |
| Alkaline Phosphatase (ALP) | K number- pending | Roche K number- K100853 |
| Device Class, Regulation Code | Class II, 21 CFR 862.1050 | Same |
| Classification Product Code | CJE | CJE |
| Intended Use | Quantitative determination of ALP | Same |
| Testing Environment | Physician office or clinical lab | Clinical lab |
| Test Principle | In the presence of magnesium ions, | |
| ALP reacts with p-NPP to release p- | ||
| nitrophenol. | In the presence of magnesium and | |
| zinc ions, p-NPP is cleaved by | ||
| phosphatases into phosphate and p- | ||
| nitrophenol | ||
| Specimen Type | Human serum or plasma | Same |
| Reportable Range | 10 to 1,000 U/L | 5 to 1,200 U/L |
| Detection Wavelength | 405/508 nm | 480/450 nm |
| Detection Limit | 5 U/L | Same |
| Linearity | 5 to 1,000 U/L | 5 to 1,200 U/L |
| Precision | %CVs range from 4.4% to 5.8% | %CVs range from 0.6% to 2.4% |
807.92 (b)(1): Brief Description of Nonclinical Data
A series of studies were performed that evaluated the following nonclinical performance characteristics for each analytical sensitivity (limits of detection), linearity, 20-day in-house precision, interference testing, in-house method comparisons, and matrices comparison between serum and heparin plasma.
Analytical Sensitivity (Limits of Detection)
The study followed CLSI EP17-A, and the limit of detection was found to be 1.8 U/L
Linearity
The study followed CLSI EP-6A, and the range of linearity was 5 U/L to 1,000 U/L.
20-day In-house Precision
The studies followed CLSI EP5-A2, where three levels of samples were each tested in two runs, twice a day, for 20 days. The results were as follows:
Page 3 of 6
Hitachi Chemical Dlagnostics, Inc.
Court, Mountain View, CA 94043-2239 Tel: 800 233 6278 Fax: 650 989 2745
3
Precision Summary:
ALP- Low, Level 1, Summary
| ALP | Within-Run | Total |
|---|---|---|
| Mean (U/L) | 42.7 | 42.7 |
| SD (U/L) | 1.30 | 2.25 |
| %CV | 3.1% | 5.3% |
ALP- Middle, Level 2, Summary
| ALP | Within-Run | Total |
|---|---|---|
| Mean (U/L) | 80.5 | 80.5 |
| SD (U/L) | 3.07 | 4.65 |
| %CV | 3.8% | 5.8% |
ALP- High, Level 3, Summary
| ALP | Within-Run | Total |
|---|---|---|
| Mean (U/L) | 555.6 | 555.6 |
| SD (U/L) | 13.99 | 24.69 |
| %CV | 2.5% | 4.4% |
Interference Testing (per CLSI EP7-A2)
The data demonstrated that the ALP test system was not affected by high levels of the following substances at the levels noted:
Hemoglobin: no interference up to 500 mg/dL Unconjugated bilirubin: no interference up to 50 mg/dL Lipemia: no interference up to 2,000 mg/dL Ascorbic acid: no interference up to 50 mg/dL
Lack of interference was defined as recoveries between 90% and 110% of the neat value, and assay performance claims were established on the HITACHI Clinical Analyzer by testing two serum pools containing approximately 12 mg/L and 80 U/L ALP.
Method Comparison
A total of 97 clinical specimens spanning the dynamic range (11 to 926 U/L), were assayed in singleton and in a blinded fashion by both the Hitachi system and a standard laboratory system. The comparative data were analyzed by linear regression and are shown below. (CI = confidence interval)
| n | r | Slope
(95% CI) | y-intercept
(95% CI) | X mean | Y mean |
|----|-------|---------------------------|-------------------------|---------|---------|
| 97 | 0.996 | 0.926
(0.909 to 0.943) | 4.8
(-0.2 to 9.8) | 203 U/L | 193 U/L |
ALP Regression Statistics:
Page 4 of 6
Chemical Chemical Diagnost
630 Clyde Court, Mountain View, CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745
4
Matrices Comparisons
A study was performed to validate the use of two plasma types as an alternative to serum for the Hitachi Clinical Analyzer with S TEST Reagent Cartridge Alkaline Phosphatase (ALP). The plasma types were sodium citrate and lithium heparin. Thirty-eight (38) matched serum/plasma samples that spanned the dynamic range (13 to 967) were assayed in singleton and the results were compared using linear regression (plasma = y-axis, each type). The performance characteristics were as follows.
N = 38
Range (serum) = 13 to 967 U/L
| Sodium Citrate Plasma | Heparinized Plasma | |
|---|---|---|
| Slope (95% CIs) | 1.03 (1.01 to 1.05) | 1.01 (1.00 to 1.02) |
| y-intercept (95% CIs) | -11.2 (-15.5 to -7.0) | -5.4 (-8.3 to -2.6) |
| r | 0.999 | 0.999 |
807.92 (b)(2): Brief Description of Clinical Data
Studies for precision and method comparison (accuracy) were performed at three external POL-type sites to evaluate the Hitachi Clinical Analyzer with S TEST Reagent Cartridges Alkaline Phosphatase (ALP) in one of its targeted intended use environments, the physician's office laboratory.
For the external site precision study, each site received three blinded serum samples (the Precision Panel, labeled A, B, and C) that were chosen to represent low, middle, and high concentrations of ALP. Each sample was assayed six times per day for five days, reporting 30 results per level. Precision estimates for total precision were as follows:
| n = 30 replicates per sample per site | ||||
|---|---|---|---|---|
| Site | Sample | Mean | Total Precision | |
| SD (U/L) | %CV | |||
| Site 1 | Low | 13.2 | 0.96 | 7.3% |
| Site 2 | Low | 12.8 | 1.00 | 7.8% |
| Site 3 | Low | 13.4 | 1.23 | 9.2% |
| Site I | Middle | 76.2 | 2.26 | 3.0% |
| Site 2 | Middle | 68.8 | 5.24 | 7.6% |
| Site 3 | Middle | 70.0 | 6.28 | 9.0% |
| Site 1 | High | 408.6 | 26.01 | 6.4% |
| Site 2 | High | 390.1 | 23.21 | 6.0% |
| Site 3 | High | 402.9 | 12.33 | 3.1% |
ALP (U/L)
Page 5 of 6
Hitachi Chemical Diagnostics, In
630 Clyde Court, Mountain View, CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745
5
For the external site method comparison study, a series of approximately 70 serum specimens with ALP values ranging from 11 to 745 U/L were assayed on the Hitachi Clinical Analyzer at three sites using S TEST Reagent Cartridge Alkaline Phosphatase (ALP) (y) and a comparative method as the reference method (x). Linear regression analysis (least squares) yielded the following results:
| Site # | n | Hitachi
Range | Regression
Equation | "r" | 95% CI
Slope | 95% CI
Intercept |
|--------|----|------------------|------------------------|------|-----------------|---------------------|
| 1 | 77 | 13 to 745 | y = 0.967x + 2.9 | 0.99 | 0.949 to 0.984 | -0.6 to 6.4 |
| 2 | 72 | 11 to 688 | y = 0.942x - 0.7 | 0.99 | 0.925 to 0.960 | -4.4 to 2.9 |
| 3 | 72 | 12 to 736 | y = 0.980x + 0.8 | 0.99 | 0.961 to 0.999 | -3.2 to 4.7 |
POL ACCURACY DATA SUMMARY- ALP (U/L)
807.92 (b)(3): Conclusions from Nonclinical and Clinical Testing
Nonclinical and clinical testing was performed for the Hitachi Clinical Analyzer with S TEST Reagent Cartridge Alkaline Phosphatase (ALP). The test system was shown to be safe and effective for its intended use.
Page 6 of 6
O Hitachi Chemical Diagnostics,
630 Clyde Court, Mountain View, CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745
6
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/6/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes representing the agency's mission to promote health, well-being, and human services. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
March 22, 2013
Hitachi Chemical Diagnostics, Inc. c/o Erika Ammirati 630 Clyde Court Mountain View, CA 94043
Re: K130141
Trade/Device Name: S TEST Reagent Cartridge Alkaline Phosphatase (ALP) Regulation Number: 21 CFR §862.1050 Regulation Name: Alkaline Phosphatase or isoenzymes test system Regulatory Class: Class II Product Code: CJE Dated: January 18, 2013 Received: January 22, 2013
Dear Ms. Ammirati:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
7
Page 2
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Carol C. Benson -S for
Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
8
Indications for Use
510(k) Number (if known): K130141
Device Name:
S TEST Reagent Cartridge Alkaline Phosphatase (ALP)
Indications for Use:
The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for the quantitative measurement of alkaline phosphatase activity in serum, lithium heparinized plasma, or sodium citrate plasma using the HITACHI Clinical Analyzer. The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
Measurements of alkaline phosphatase are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases.
Prescription Use X (21 CFR Part 801 Subpart D)
And/Or
Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)
Ruth A. Cheslêr -S
Division Sign-Off Office of In Vitro Diagnostics and Radiological Health (OIR)
K130141 510(k)